Bruker Co. (NASDAQ:BRKR) Stock Holdings Cut by Numerai GP LLC

Numerai GP LLC lessened its position in Bruker Co. (NASDAQ:BRKR) by 21.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 24,129 shares of the medical research company’s stock after selling 6,751 shares during the quarter. Numerai GP LLC’s holdings in Bruker were worth $1,414,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BRKR. London Co. of Virginia raised its position in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock worth $245,820,000 after acquiring an additional 1,843,294 shares in the last quarter. FIL Ltd lifted its stake in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Norges Bank bought a new stake in Bruker during the fourth quarter worth approximately $63,378,000. Marshall Wace LLP increased its holdings in shares of Bruker by 4,510.3% in the fourth quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company’s stock valued at $45,957,000 after buying an additional 766,983 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its position in shares of Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after acquiring an additional 666,617 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BRKR shares. UBS Group cut their target price on Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. The Goldman Sachs Group cut their price objective on Bruker from $50.00 to $45.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Barclays dropped their target price on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday, April 17th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.10.

Bruker Stock Performance

BRKR stock opened at $38.74 on Wednesday. The firm has a 50 day simple moving average of $40.94 and a 200 day simple moving average of $50.89. Bruker Co. has a 52 week low of $34.10 and a 52 week high of $79.78. The stock has a market cap of $5.87 billion, a P/E ratio of 50.97, a P/E/G ratio of 2.16 and a beta of 1.23. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The company had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. During the same quarter last year, the business posted $0.53 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Research analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Monday, March 17th. Bruker’s payout ratio is currently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.